Open Access

Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C22H29FO5) intratympanic injection

  • Authors:
    • Cristian Mârțu
    • Sebastian Cozma
    • Bogdan Cobzeanu
    • Doina Vesa
    • Corina Butnaru
    • Dragoș Bularda
    • Adeline Cumpătă
    • Luminița Rădulescu
  • View Affiliations

  • Published online on: December 7, 2021     https://doi.org/10.3892/etm.2021.11048
  • Article Number: 125
  • Copyright: © Mârțu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long‑term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non‑acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two‑year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long‑term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow‑up occurred at one month, one year and three years later.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mârțu C, Cozma S, Cobzeanu B, Vesa D, Butnaru C, Bularda D, Cumpătă A and Rădulescu L: Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>) intratympanic injection. Exp Ther Med 23: 125, 2022
APA
Mârțu, C., Cozma, S., Cobzeanu, B., Vesa, D., Butnaru, C., Bularda, D. ... Rădulescu, L. (2022). Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>) intratympanic injection. Experimental and Therapeutic Medicine, 23, 125. https://doi.org/10.3892/etm.2021.11048
MLA
Mârțu, C., Cozma, S., Cobzeanu, B., Vesa, D., Butnaru, C., Bularda, D., Cumpătă, A., Rădulescu, L."Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>) intratympanic injection". Experimental and Therapeutic Medicine 23.2 (2022): 125.
Chicago
Mârțu, C., Cozma, S., Cobzeanu, B., Vesa, D., Butnaru, C., Bularda, D., Cumpătă, A., Rădulescu, L."Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>) intratympanic injection". Experimental and Therapeutic Medicine 23, no. 2 (2022): 125. https://doi.org/10.3892/etm.2021.11048